Stay updated on Pembrolizumab in Neuroendocrine Tumors Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Neuroendocrine Tumors Clinical Trial page.

Latest updates to the Pembrolizumab in Neuroendocrine Tumors Clinical Trial page
- Check6 days agoChange DetectedRevision: v3.5.4 was added and Revision: v3.5.3 was removed, indicating a software version update on the page. The underlying study content and navigation remain unchanged.SummaryDifference0.1%

- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedThe study record's revision label was updated from v3.5.2 to v3.5.3, indicating a new version of the entry. This update reflects a metadata revision rather than changes to the study content, eligibility, or results.SummaryDifference0.1%

- Check27 days agoNo Change Detected
- Check34 days agoChange DetectedRevision label updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check56 days agoChange DetectedRevision from v3.4.3 to v3.5.0. There are no visible changes to the study details, outcomes, or eligibility criteria on the page.SummaryDifference0.1%

- Check70 days agoChange DetectedSite revision updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check98 days agoChange DetectedRevision: v3.4.2 has been added to the page. The government funding status warning banner about potential outages has been removed.SummaryDifference0.5%

Stay in the know with updates to Pembrolizumab in Neuroendocrine Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Neuroendocrine Tumors Clinical Trial page.